Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

Bibliographic Details
Main Authors:	Timothy Fitzgerald, Maryia Zhdanava, Dominic Pilon, Aditi Shah, Patrick Lefebvre, Steven R. Feldman
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2023-09-01
Series:	Dermatology and Therapy
Subjects:	Biologics Guselkumab Persistence Psoriasis Remission Treatment discontinuation
Online Access:	https://doi.org/10.1007/s13555-023-01017-8

Similar Items

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Timothy Fitzgerald, et al.
Published: (2023-03-01)

Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study
by: Andrew Blauvelt, et al.
Published: (2022-05-01)

Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study
by: Li Y, et al.
Published: (2022-10-01)

Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab
by: Erin Bartholomew, et al.
Published: (2023-09-01)

Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Andrew Blauvelt, et al.
Published: (2023-09-01)

Efficacy of guselkumab compared with adalimumab for psoriasis: a meta-analysis of randomized controlled studies
by: Hongyi Fu, et al.
Published: (2022-11-01)

Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab
by: Kristian Reich, et al.
Published: (2020-08-01)

Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient: a case report
by: Nicoletta Bernardini, et al.
Published: (2022-07-01)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
by: Light JG, et al.
Published: (2021-01-01)

Work/study productivity gain and associated indirect cost savings with guselkumab compared with adalimumab in moderate-to-severe psoriasis: results from the VOYAGE 1 study
by: N. Li, et al.
Published: (2022-01-01)

Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2
by: Luis Puig, et al.
Published: (2021-07-01)

Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives
by: Ricardo Ruiz-Villaverde, et al.
Published: (2022-09-01)

Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis
by: Cathrine Dawn Büttner Elgaard, et al.
Published: (2023-12-01)

Cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasis
by: Amanda Teeple, et al.
Published: (2022-01-01)

Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center
by: Seung-Won Jung, et al.
Published: (2022-05-01)

Successful treatment of generalized pustular psoriasis with guselkumab
by: Martina Part
Published: (2024-12-01)

Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis
by: Ana-Maria Orbai, et al.
Published: (2023-09-01)

Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis
by: Marloes E. van Muijen, et al.
Published: (2022-08-01)

Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany
by: Matthias Augustin, et al.
Published: (2022-02-01)

Seven cancer patients receiving Guselkumab for treatment of moderate-to-severe psoriasis
by: Luca Mastorino, et al.
Published: (2022-03-01)

Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
by: Kristian Reich, et al.
Published: (2024-02-01)

Based on Gene Expression Analysis: Low-Density Neutrophil Expression Is a Characteristic of the Fast Responders Treated With Guselkumab for Psoriasis
by: Jiajing Lu, et al.
Published: (2022-05-01)

Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab
by: Blauvelt A, et al.
Published: (2020-03-01)

Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis
by: Yang EJ, et al.
Published: (2019-06-01)

Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2
by: Byung Soo Kim, et al.
Published: (2023-09-01)

Management of Plaque Psoriasis: A Review and Comparison of IL-23 Inhibitors
by: Nicole L. Bolick, et al.
Published: (2020-12-01)

Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period
by: Chan Y, et al.
Published: (2021-06-01)

Erythrodermic psoriasis after discontinuation of ixekizumab
by: Kathryn Anne Potter, MD, et al.
Published: (2018-01-01)

Guselkumab in the treatment of patients with plaque psoriasis of moderate and severe severity: Efficacy and safety of interleukin-23 blockade
by: V. V. Chikin
Published: (2020-01-01)

Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience
by: Matteo Megna, et al.
Published: (2022-02-01)

Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study
by: Matteo Megna, et al.
Published: (2022-07-01)

Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis
by: Jianfeng Zheng, et al.
Published: (2023-12-01)

Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study
by: Marco Galluzzo, et al.
Published: (2020-07-01)

Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1
by: Christopher E. M. Griffiths, et al.
Published: (2022-02-01)

Axonal sensorimotor polyneuropathy after starting guselkumab
by: Issam Hamadah, et al.
Published: (2022-05-01)

Current advances in biological therapy of psoriasis: efficacy of guselkumab in real clinical practice
by: O. V. Zhukova, et al.
Published: (2022-03-01)

Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry
by: Jan Hugo, et al.
Published: (2023-02-01)

Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn’s disease
by: Hannah S. Berman, et al.
Published: (2021-02-01)

Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class
by: Ahmed Bagit, BSc, et al.
Published: (2023-09-01)

Transcription Factor IRF7 is Involved in Psoriasis Development and Response to Guselkumab Treatment
by: Yuan X, et al.
Published: (2024-02-01)